Taysha | IPO Presentation Deck | 66 slides · page 34 of 66
The chart shows survival rates over 35 weeks for various dosage groups of AAV9/MECP2 and TSHA-102.
Pitch deck · appendix_data · analyze_data · balanced density
Slide locked Sign in to view
Slide schematic 4/4
callout 1/1 chart 1/1 source-note 1/1 title 1/1
Components 4
primary line source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.